Bacillus anthracis is an aerobic, spore-forming bacterium that causes anthrax disease. Anthrax occurs globally, especially in agricultural areas that do not have a livestock vaccination program. Naturally occurring anthrax is rare in the United States, which has successful vaccination programs among livestock and strict importation regulations. In 2001, anthrax bacteria were used in bioterrorism attacks involving the postal system and government buildings. Regardless of the cause, all suspected cases of anthrax must be reported to the local health department for investigation.
Anthrax bacteria infect people and animals when spores are inhaled, ingested, or enter the body through a break in the skin. Once inside the body, the spores replicate and produce three proteins: edema factor (EF), lethal factor (LF), and protective antigen (PA). It is the combination of these proteins that is believed to cause tissue damage, shock, and death. Sometimes there is a delayed onset of anthrax disease. This is because anthrax spores can remain in the lungs for weeks without replicating. Antibiotics do not kill the spores. When the spores finally do replicate, anthrax disease develops.
There are three forms of anthrax disease:
Antibiotics, such as ciprofloxacin, doxycycline, and amoxicillin, are the most important therapeutic interventions for any form of anthrax. A combination of antibiotics needs to be started as soon as the disease is suspected. In addition, aggressive supportive care will be needed.
In 1991, DoD Service members deploying for the Persian Gulf War received one or two doses of anthrax vaccine, labeled Vaccine A or Vacc A. Other abbreviations for anthrax vaccine include AVA and ANT. Before November 2008, the vaccine was given as a 6-dose series. Research on the vaccine showed, however, that five doses are as effective as six doses in preventing anthrax. So, in November 2008, the primary series of anthrax vaccine was changed to five doses. See "Dose/Schedule" for more information.
Product: Biothrax® (Anthrax Vaccine Adsorbed)
Manufacturer: Emergent BioDefense Operations Lansing Inc
Year licensed: 1970
Pregnant women who have received the anthrax vaccine during pregnancy should receive regular prenatal care and should discuss their anthrax vaccination with their healthcare provider and/or obstetrician. IHB has the latest information regarding pregnancy and vaccination, as well as adverse event research. IHB also offers pregnancy monitoring for women inadvertently vaccinated during pregnancy. For more information, please visit the Pregnancy page or contact IHB.
Brachman PS, Friedlander AM, Grabenstein JD. Anthrax. In: Plotkin SA, Orenstein WA, Vaccines, 4th ed. Philadelphia: W. B. Saunders, 2003.
Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. American Journal of Public Health 1962;52:432-45. http://www.anthrax.mil/documents/338field_eval.pdf
Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States. MMWR-Morbidity & Mortality Weekly Report 2000;49(RR-15):1-20. http://www.cdc.gov/mmwr/PDF/rr/rr4915.pdf
Food & Drug Administration. Biological products; Bacterial vaccines and toxoids; Implementation of efficacy review. Federal Register 1985;50:51002-117. http://www.anthrax.mil/documents/338field_eval.pdf
Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr. Clinical recognition and management of patients exposed to biological warfare agents. Journal of the American Medical Association 1997;278(Aug 6):399-411. http://jama.ama-assn.org/cgi/content/short/278/5/399
Hambleton P, Carman JA, Melling J. Anthrax: The disease in relation to vaccines. Vaccine 1984;2:125-32.
Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, , Parker G, Perl TM, Russell PK, Tonat K, Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: Updated Recommendations for Management. Journal of the American Medical Association 2002;287:2236- 52. http://jama.ama-assn.org/cgi/content/short/287/17/2236
Ivins BE, Fellows PF, Pitt MLM, Estep JE, Welkos SL, Worsham PL, Friedlander AM. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Medical Bulletin 1996;87(Suppl): 125-6.
Ivins BE, Pitt MLM, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW Jr., Gibbs PH, Friedlander AM. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998;16:1141-8.
Pitt MLM, Ivins BE, Estep JE, et al. Comparison of the efficacy of purified protective antigen and MDPH to protect non-human primates from inhalation anthrax. Salisbury Medical Bulletin. 1996;87:130.
Sidell FR, Takafuji ET, Franz DR. Medical Aspects of Chemical & Biological Warfare. Washington, DC: Department of the Army, 1997.
Turnbull PCB. Guidelines for the Surveillance and Control of Anthrax in Humans and Animals, 3rd ed., WHO Report WHO/EMC/ZDI/98.6.